###begin article-title 0
###xml 72 78 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 68 71 <span type="species:ncbi:10116">rat</span>
Functional interactions between an atypical NF-kappaB site from the rat CYP2B1 promoter and the transcriptional repressor RBP-Jkappa/CBF1
###end article-title 0
###begin p 1
To whom correspondence should be addressed. Tel: +1 972 883 6882; Fax: +1 972 231 0628; Email: dejong@utdallas.edu Present address: Xiao-li Wang, Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
###end p 1
###begin p 2
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP</italic>
###xml 583 589 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 590 591 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 676 684 652 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 841 848 813 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 911 917 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 918 919 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1182 1188 1134 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1189 1190 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 28 31 <span type="species:ncbi:10116">rat</span>
###xml 278 281 <span type="species:ncbi:10116">rat</span>
###xml 857 861 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1089 1092 <span type="species:ncbi:10116">rat</span>
The phenobarbital-inducible rat cytochrome P450 (CYP) 2B1 and 2B2 proteins are encoded by homologous genes whose promoters contain a mammalian-apparent long terminal repeat retrotransposon (MaLR). An NF-kappaB-like site within the MaLR forms multiple protein-DNA complexes with rat liver and HeLa cell nuclear extracts. Using antibody supershift assays, we have identified these complexes as NF-kappaB and RPB-Jkappa/CBF1. Competition assays using a series of single site mutant oligonucleotides reveal that the recognition sites for these two factors overlap. We also show that the CYP2B1/2 NF-kappaB element, but not the Igkappa NF-kappaB element, can repress transcription in vitro when positioned upstream of the heterologous adenovirus major late core promoter. In addition, RBP-Jkappa overexpressed in COS-7 cells repressed expression in vivo from an SV40-luciferase reporter construct that contained the CYP2B1/2 NF-kappaB element. Finally, we observe similar levels of NF-kappaB and RBP-Jkappa binding activities in nuclear extracts prepared from control and phenobarbital-induced rat livers. The results suggest that RBP-Jkappa/CBF1 binds an atypical NF-kappaB site in the CYP2B1/2 promoters and may help to maintain a low level of expression in the absence of inducer.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP</italic>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP450</italic>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c1">1</xref>
Cytochrome P450s (CYP) are heme-containing membrane proteins that metabolize both foreign (xenobiotic) chemicals and endogenous compounds. Individual members of the CYP450 gene superfamily are regulated in developmental-, tissue-, and gender-specific patterns and, in some cases, are activated by exposure to chemical inducers (1).
###end p 4
###begin p 5
###xml 25 34 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP4502B1</italic>
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B2</italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c2">2</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c5">5</xref>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B2</italic>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c6">6</xref>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c7">7</xref>
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c8">8</xref>
###xml 726 733 726 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c9">9</xref>
###xml 901 908 901 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp2b10</italic>
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 983 985 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c12">12</xref>
###xml 1083 1106 1083 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bacillus megaterium CYP</italic>
###xml 1109 1113 1109 1113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">BM-1</sub>
###xml 1118 1121 1118 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP</italic>
###xml 1124 1128 1124 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">BM-3</sub>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c13">13</xref>
###xml 21 24 <span type="species:ncbi:10116">rat</span>
###xml 669 684 <span type="species:ncbi:10090">transgenic mice</span>
###xml 895 900 <span type="species:ncbi:10090">mouse</span>
###xml 1083 1102 <span type="species:ncbi:1404">Bacillus megaterium</span>
Transcription of the rat CYP4502B1 and 2B2 genes (CYP2B1/2) is driven by liver-specific promoters that are ~96% identical within 2.35 kb upstream of the transcription initiation site. These promoters are notable for their ability to be induced up to several hundred-fold by the barbiturate sedative phenobarbital (PB) or other 'PB-like' inducers. Several regions from the CYP2B1/2 promoters are proposed to contain PB-responsive elements (PBRE) (reviewed in 2-5) and the most compelling evidence points to a distal element between -2318 and -2155 identified by assaying the activity of CYP2B2 promoter constructs transfected into primary hepatocytes (6). Studies using transgenic mice confirm a role for this region (7,8) and in vivo footprinting shows PB-dependent alterations in chromatin structure (9). Genetic and biochemical characterization of the corresponding region from the homologous mouse Cyp2b10 promoter suggests a role for NF-1 and the orphan nuclear receptor CAR (10-12). These sequences are distinct from the 'barbie box' element responsible for PB-induction of the Bacillus megaterium CYP450BM-1 and CYP450BM-3 genes (13).
###end p 5
###begin p 6
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c7">7</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c14">14</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c16">16</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c3">3</xref>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B2</italic>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c7">7</xref>
###xml 518 525 518 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B2</italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c16">16</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c17">17</xref>
###xml 31 34 <span type="species:ncbi:10116">rat</span>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
###xml 269 272 <span type="species:ncbi:10116">rat</span>
###xml 351 366 <span type="species:ncbi:10090">transgenic mice</span>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
In the absence of inducer, the rat CYP2B1/2 and mouse CYP2b10 genes are expressed at very low basal levels and may be maintained in a constituitively repressed state via negative regulatory elements (7,10,14-16; reviewed in 3). For instance, a construct that contained rat CYP2B2 promoter proximal sequences (to -0.8 kb) was constituitively active in transgenic mice, whereas constructs that included additional upstream sequences (to -19 kb) suppressed basal activity (7). In addition, deletion analysis of the mouse CYP2b10 promoter revealed that sequences between -971 and -775 reduced thymidine kinase promoter-CAT activity (10). Similarly, a 3-fold reduction in luciferase activity was seen with CYP2B2 constructs containing sequences from -725 to -1400 that were transfected into HepG2 cells (16). Of additional interest is the fact that these reports focus on a region of the promoter that shares homology with a family of mammalian-apparent long terminal repeat retrotransposon (MaLR) elements (17).
###end p 6
###begin p 7
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 183 185 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c18">18</xref>
###xml 208 210 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c19">19</xref>
###xml 326 334 310 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 339 346 323 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
In this report we identify and characterize an element within the CYP2B1/2 MaLR that is recognized by both NF-kappaB and the recombination signal sequence-binding protein RBP-Jkappa (18), also known as CBF1 (19). The dual NF-kappaB/RBP-Jkappa sequence element, when fused to a heterologous promoter, can inhibit transcription in vitro and in vivo. The results support a role for RBP-Jkappa/CBF1 as a constitutively active nuclear repressor that can bind to a distinct class of NF-kappaB sites.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Oligonucleotides
###end title 9
###begin p 10
###xml 984 990 952 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 991 992 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
For band shift and competition experiments: NF-kappaB 2B1/2, 5'-ACTGTGGGAAATTCCACACC-3'; NF-kappaB Igkappa, 5'-CAGAGGGGACTTTCCGAGAG-3'; AP-1 wt, 5'-GTGTCTGACTCATGCTT-3'; AP-1A, 5'-TCTCAAATGACTCTAGCTTG-3'; AP-1B, 5'-TCCATTTGACTCCTGAGCCT-3'; AP-1mut, 5'-CTCAAATTATTCTAGCTT-3'; AdML TATA, 5'-AAGGGGGGCTATAAAAGGGGGTGGG-3'; Sp1, 5'-TTCGATCGGGGCGGGGCGAG-3'; 2B1/2DR, 5'-CTGATTTCTTACAGAACCCAAGACTTTCTTACAGAAGTCC-3'; 2B1/2 core, 5'-GTGGAGGGGCGGATTCAGCATAAAAGATCCTGC-3'; C/EBP, 5'-TGCAGATTGCGCAATCTGCA-3'. For construction of transcription templates: NF-kappaB Igkappa 5'-CAGAGGGGACTTTCCGAGAGTACTGCATGCAGAGGGGACTTTCCGAGAGTACTGCATG-3'; NF-kappaB 2B1/2, 5'-CATGCAGTACTGTGGGAAATTCCACACCGCATGCAGTACTGTGGGAAATTCCACACCG-3'. For construction of RBP-Jkappa expression vectors: RBP-myc5', 5'-CGCCGCGGATCCAGTAATGCCCTCCGGTTTTCCT-3'; RBP-myc3', 5'-CCBCCBCTCGAGGGACACCACGGTTGCTGT-3'. For construction of pGL3-Pro-based reporter templates: Igkappa promoter, 5'-AGCGAGCTCGATATCAGAGGGGACTTTCCGAGAGCTAGCCG-3'; CYP2B1/2 promoter, 5'-AGCGAGCTCGATATCACTGTGGGAAATTCCACACCGCTAGCTAG-3'. Oligos were obtained from Operon.
###end p 10
###begin title 11
Preparation of nuclear extracts
###end title 11
###begin p 12
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c20">20</xref>
###xml 1008 1009 1008 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 84 103 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 1432 1438 <span type="species:ncbi:9913">bovine</span>
Nuclear extracts were prepared essentially as described by Gorski et al. (20). Male Sprague-Dawley rats (~150-200 g; Zivic-Miller Laboratories) were given either no injection or i.p. injections of either saline (control) or 100 mg/kg PB (Sigma) 20 h prior to sacrifice. Livers were removed and homogenized in 10 ml/g ice-cold homogenization buffer (10 mM HEPES pH 7.6, 15 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M sucrose, 10% glycerol, 0.5 mM DTT, 0.5 mM PMSF and 1% Trasylol) through three passes in a glass-teflon homogenizer using a Glas-Col motor at a setting of 60. The resulting homogenate was layered onto 2 M sucrose cushions, centrifuged at 24 000 r.p.m. for 60 min and the cytoplasmic extract (supernatant) and pelleted nuclei were collected. Cytoplasmic extracts were dialyzed against dialysis buffer (25 mM HEPES pH 7.6, 40 mM KCl, 0.1 mM EDTA, 10% glycerol and 1 mM DTT) prior to use. Nuclei were resuspended in nuclear lysis buffer (10 mM HEPES, pH 7.6, 100 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 10% glycerol, 1 mM DTT, 0.1 mM PMSF and 1% Trasylol) and chromatin was pelleted by addition of 0.3 g/ml ammonium sulfate and centrifugation at 35 000 r.p.m. for 60 min. The upper aqueous nuclear extract was recovered and dialyzed. Extracts were aliquoted and snap frozen for storage at -70degreesC. Protein concentrations were typically 4-8 mg/ml and were determined using the Bradford method (Bio-Rad) with bovine serum albumin as the standard.
###end p 12
###begin title 13
Electrophoretic mobility shift assays
###end title 13
###begin p 14
###xml 164 166 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c21">21</xref>
###xml 612 614 594 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1166 1168 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c22">22</xref>
###xml 1544 1549 <span type="species:ncbi:10090">mouse</span>
Binding reactions (25 microl) were performed in 10 mM HEPES, pH 7.9, 60 mM KCl, 2% PEG-8000 (w/v), 0.2 mM EDTA, 8% glycerol and 0.1 mg/ml poly(dI-dC) as described (21). Reactions contained 6-10 microg of either nuclear or cytoplasmic proteins prepared from untreated animals, from the livers of saline-treated (control) or PB-induced animals, or from HeLa cells. Oligonucleotides were typically purified by Sephadex G-25 gel filtration and annealed by incubating at 75degreesC for 5 min and cooling slowly to room temperature. Purified oligonucleotides were radiolabeled with T4 polynucleotide kinase and [gamma-32P]ATP and separated from unreacted nucleotides by purification with 1 ml Sephadex G-25 columns. Labeled oligonucleotides (~70 fmol) corresponding to 50 000-100 000 c.p.m. were added to reactions, which proceeded for 45 min at 4degreesC. The resulting protein-DNA complexes were loaded onto 0.5x TBE, 5% polyacrylamide gels and electrophoresed in 0.5x TBE running buffer. Unlabeled oligonucleotide competitors used in competition experiments were present in 100-fold excess over probe. In experiments where NF-kappaB was post-translationally activated (22), various combinations of Nonidet P-40 (NP-40) (2.4%), formamide (27%) and sodium deoxycholate (DOC) (0.4%) were added to the reaction mixtures as indicated. Results were visualized by drying the gels and exposing to X-OMAT AR film (Kodak). Supershift reactions contained 0.5-2 microl of antibodies specific for the p50, p52, or p65 subunit of NF-kappaB (Santa Cruz), or for mouse RBP-Jkappa (K0043), and were added prior to the addition of probe.
###end p 14
###begin title 15
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro transcription assays
###end title 15
###begin p 16
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 346 354 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 380 382 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c20">20</xref>
###xml 383 385 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c23">23</xref>
###xml 446 447 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 504 506 476 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 542 543 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 680 683 628 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
Templates for in vitro transcription were based on pMLG4G, a G-free cassette reporter driven by the adenovirus major late (AdML) core promoter. Constructs were prepared by the insertion of synthetic double-stranded oligonucleotides containing either tandem NF-kappaB 2B1/2 sites (pMLG4G-2B1/2) or tandem NF-kappaB Igkappa sites (pMLG4G-Igkappa). In vitro transcription reactions (20,23) were performed in 25 mM HEPES, pH 7.6, 50 mM KCl, 6 mM MgCl2, 0.6 mM ATP, 0.6 mM UTP, 35 microM CTP, 1 microl [alpha-32P]CTP (800 Ci/mmol; ICN), 0.1 mM 3'-O-methyl-GTP (Pharmacia), 12% glycerol, 1 microl RNasin (approximately30 U; Pharmacia). Reactions (50 microl) also contained 20 microg/ml HindIII-digested linear DNA template and approximately70 microg HeLa cell nuclear extract. After 45 min incubation at 30degreesC, the reactions were terminated by the addition 280 microl stop mix (300 mM sodium acetate, 50 mM EDTA and 1.2% SDS). Proteins were removed by proteinase K treatment (10 microl of 20 mg/ml proteinase K, 0.5 mg/ml tRNA) for 20 min at 55degreesC. After phenol/chloroform (1:1) extraction, labeled RNA was precipitated by addition of 350 microl of 100% ethanol. The RNA pellets were rinsed with 80% ethanol and dried for 5 min under vacuum. Pellets were resuspended in 5 microl of RNA loading dye (95% formamide, 1 mM EDTA and 0.05% bromophenol blue and xylene cyanol) and loaded onto 7 M urea-5% polyacrylamide sequencing gels. NF-kappaB 2B1/2 oligonucleotide competitor was added to 0.28 microM.
###end p 16
###begin title 17
Transfections
###end title 17
###begin p 18
###xml 157 160 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 166 169 162 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 245 248 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 254 257 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 448 454 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 455 456 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 524 527 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 529 532 521 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nhe</italic>
The open reading frame of RBP-Jkappa was PCR amplified from the RBP-2 cDNA using the RBP-myc5' and RBP-myc3' oligonucleotides. The product was digested with XbaI and BamHI and subcloned into pcDNA3.1/myc-His (Invitrogen). The insert produced by XhoI and BamHI digestion of this plasmid was then subcloned into pCMV-Tag 2 (Stratagene) to generate pCMV-RBP. Reporter constructs were generated by subcloning synthetic NF-kappaB binding sites from the CYP2B1/2 promoter or IgK enhancer into the pGL3 Pro vector (Promega) at the SacI-NheI site.
###end p 18
###begin p 19
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c24">24</xref>
###xml 213 219 <span type="species:ncbi:9913">bovine</span>
Transient transfections were performed using the calcium phosphate precipitate method (24). COS-7 cells were grown on 6-well plates containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone). When cells were 50% confluent they were co-transfected with 3 microg pGL3-Pro-based reporter constructs together with pCMV-RBP. An aliquot of 200 ng of pCMV-betaGAL was added as a control for transfection efficiency. Cells were harvested 48 h after transfection, and luciferase assays using 20 microl of cellular extracts were performed as described by the manufacturer (Promega) using a Turner TD-20e luminometer. Experiments were performed in triplicate.
###end p 19
###begin p 20
###xml 210 212 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c25">25</xref>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
Measurement of RBP-Jkappa in COS-7 cells was performed with the cellular lysates used for the luciferase assay. Immunoblotting was performed using the ECL system (Amersham) and an anti-myc monoclonal antibody (25) prepared from mouse cell line MYC1-9E10.2 (ATCC).
###end p 20
###begin title 21
Other techniques
###end title 21
###begin p 22
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c24">24</xref>
Other molecular biology techniques were performed as described (24). Quantitation of autoradiographs was performed using an LKB Ultroscan XL laser densitometer or a Molecular Dynamics phosphorimager. Sequences were analyzed using the Lasergene software package (DNASTAR), BLAST sequence homology searches at NCBI (http://www.ncbi.nlm.nih.gov/ ) and the TRANSFAC and TESS programs (http://dot.imgen.bcm.tmc.edu:9331/seq-search/gene-search.html ) to predict binding sites for transcription factors.
###end p 22
###begin title 23
RESULTS
###end title 23
###begin title 24
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B1</italic>
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B2</italic>
###xml 30 33 <span type="species:ncbi:10116">rat</span>
Structure of the PB-inducible rat cytochrome P450 2B1 and 2B2 gene promoters
###end title 24
###begin p 25
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c6">6</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c11">11</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c17">17</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c26">26</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c16">16</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c27">27</xref>
###xml 602 609 602 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 596 601 <span type="species:ncbi:10090">mouse</span>
The direction and location of selected sequence elements in the CYP2B1/2 promoters are summarized in Figure 1A. These include a PBRE between -2318 and -2155 (6,10,11), an MaLR long terminal repeat (LTR) between -1242 and -739 (17), a glucocorticoid response element (26), a core promoter region that contains sites for C/EBP (16,27), TBP and Sp1 and a region of repetitive CA dinucleotides. Regions upstream of -2.35 kb are not homologous, but include distinct truncations of LINE-1 repetitive elements and GA dinucleotide repeats of different lengths. The available sequence of the PB-inducible mouse CYP2b10 (1.4 kb) promoter is ~83% identical to the CYP2B1/2 gene (10).
###end p 25
###begin p 26
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 19 20 19 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c28">28</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c17">17</xref>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 667 668 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 766 768 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c29">29</xref>
###xml 958 964 951 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 965 966 958 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1068 1070 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c30">30</xref>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Analysis of CYP2B1/2 sequences between -1242 and -739 showed ~68% identity to 400 nt of the mouse MTa repetitive element (28). This region is thus a member of a large family (40 000-100 000 estimated copies) of retrotransposon-like MaLR repetitive elements often found as solitary, inactive LTRs (17). We tentatively divided the CYP2B1/2 MaLR into U3, R and U5 regions oriented away from the direction of CYP2B1/2 transcription (Fig. 1A). Computer analysis of the U3 region revealed that it contains a short direct repeat of 12 nt, as well as two adjacent sequences that resemble the GGGRNNYYCC recognition site for the inducible transcription factor NF-kappaB (Fig. 1B). One of these sites (GGGAAATTCC) exactly matches a site found in the beta-interferon enhancer (29). These sequences were of interest because little is known as to whether MaLR elements regulate expression of adjacent cellular genes and because of the possibility of a connection between CYP2B1/2 induction and the responsiveness of rel (NF-kappaB) family transcription factors to chemical stress (30).
###end p 26
###begin title 27
###xml 26 32 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 33 34 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 77 80 <span type="species:ncbi:10116">rat</span>
The NF-kappaB site in the CYP2B1/2 LTR is recognized by multiple proteins in rat liver nuclear extracts
###end title 27
###begin p 28
###xml 117 123 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 124 125 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 287 288 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f2">2</xref>
###xml 429 431 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c31">31</xref>
###xml 485 486 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 488 489 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 656 657 628 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 902 903 862 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1197 1198 1149 1150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1223 1224 1175 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f2">2</xref>
###xml 1268 1269 1220 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 16 19 <span type="species:ncbi:10116">rat</span>
To determine if rat liver nuclei contained factors that would selectively recognize the NF-kappaB element within the CYP2B1/2 MaLR, we tested the ability of oligonucleotides that span this region (denoted NF-kappaB 2B1/2) to form complexes in electrophoretic mobility shift assays (Fig. 2A). For comparison we used a control oligonucleotide that contains the NF-kappaB site from the Igkappa enhancer (denoted NF-kappaB Igkappa) (31). The control probe detected up to three complexes (C2-C4) in this experiment (lane 1). The NF-kappaB 2B1/2 probe revealed complexes of approximately similar mobility, but also formed an abundant, faster migrating species (C1) (lane 4). Competition experiments using unlabeled oligonucleotides showed that the upper set of complexes were efficiently competed by both NF-kappaB 2B1/2 and NF-kappaB Igkappa competitors (lanes 2, 3, 5 and 6), while formation of the major C1 complex was abolished only in the presence of the NF-kappaB 2B1/2 competitor (lane 6). To further establish that these results were not due to recognition of the NF-kappaB 2B1/2 probe by a non-specific factor, additional oligonucleotide competitors were tested for their ability to eliminate C1 complex formation (Fig. 2B). The results show that formation of the C1 complex was abolished only in the presence of NF-kappaB 2B1/2 competitor (lane 3).
###end p 28
###begin title 29
Factors that recognize the NF-kappaB 2B1/2 element show differential localization and responsiveness to protein-dissociating reagents
###end title 29
###begin p 30
###xml 245 247 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c22">22</xref>
###xml 269 270 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f3">3</xref>
###xml 461 462 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 578 579 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f3">3</xref>
###xml 626 627 614 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 77 80 <span type="species:ncbi:10116">rat</span>
Binding activities present in nuclear and cytoplasmic extracts prepared from rat livers were compared in the presence of dissociating agents such as NP-40, DOC and formamide that release active NF-kappaB from its cytoplasmic inhibitor I-kappaB (22). As shown in Figure 3, band shift experiments with the NF-kappaB 2B1/2 probe demonstrate that the upper complexes could be activated by various dissociating agents (for example lanes 5 and 12). In contrast, the C1 complex was restricted to the nuclear fraction and was unaffected by addition of protein-dissociating agents (Fig. 3B, lanes 1-7). These results suggest that the C1 complex contains a distinct nuclear factor that recognizes this particular NF-kappaB site, or an adjacent or overlapping sequence.
###end p 30
###begin title 31
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
The CYP2B1/2 NF-kappaB element is recognized by NF-kappaB and RBP-Jkappa
###end title 31
###begin p 32
###xml 169 176 157 164 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GTGGGAA</underline>
###xml 215 217 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c32">32</xref>
###xml 228 229 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 414 415 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f4">4</xref>
###xml 774 775 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1078 1079 1046 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1172 1179 1136 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp2b10</italic>
###xml 1191 1192 1155 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 717 722 <span type="species:ncbi:10090">mouse</span>
###xml 1166 1171 <span type="species:ncbi:10090">mouse</span>
Interestingly, the NF-kappaB 2B1/2 sequence (but not the NF-kappaB Igkappa control oligonucleotide) contains an overlapping site (GTGGGAA) that matches a concensus ag/cCGTGGGAActa/t RBP-Jkappa recognition sequence (32; see Fig. 1B). To verify whether these proteins are present in the upper and lower complexes, we performed band shift experiments in the presence of factor-specific antibodies. As shown in Figure 4, addition of antibodies for the p50 (lanes 2 and 7) and p65 (lanes 3 and 8) subunits of NF-kappaB, but not for the p52 subunit (lanes 4 and 9), resulted in disappearance of the upper complex and formation of slower migrating complexes. Likewise, addition of a monoclonal antibody (K0043) specific for mouse RBP-Jkappa resulted in disappearance of the lower C1 complex and formation of an upper complex (lanes 5 and 10) that migrated just above the position of the NF-kappaB complex (lane 1). The antibodies themselves do not shift the probe (lanes 11-14). This experiment demonstrates that the upper complexes contain NF-kappaB-like proteins, whereas the lower C1 complex is due to RBP-Jkappa/CBF1. Interestingly, the corresponding sequence from the mouse Cyp2b10 gene (Fig. 1B) is also recognized by both NF-kappaB and RBP-Jkappa (data not shown).
###end p 32
###begin title 33
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
The CYP2B1/2 NF-kappaB element contains overlapping NF-kappaB and RBP-Jkappa recognition sequences
###end title 33
###begin p 34
###xml 205 206 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f5">5</xref>
###xml 330 331 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f5">5</xref>
###xml 408 411 392 395 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGG</underline>
###xml 412 414 396 398 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AA</underline>
###xml 632 635 608 611 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GTG</underline>
###xml 636 639 612 615 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GAA</underline>
To investigate the NF-kappaB 2B1/2 recognition sequence in more detail, we synthesized a series of oligonucleotides that contained mutations in the putative RBP-Jkappa or NF-kappaB recognition sites (Fig. 5A). These oligonucleotides were used as competitors in band shift assays using the NF-kappaB 2B1/2 probe. The results (Fig. 5B) show that oligonucleotides with mutations in underlined positions of ACTGTGGGAAATTCCACACC competed poorly for NF-kappaB complex formation, consistent with the idea that these positions are important for NF-kappaB binding. Likewise, oligonucleotides with mutations in the underlined positions of ACTGTGGGAAATTCCACACC competed poorly for binding of RBP-Jkappa, indicating that these positions are important for RBP-Jkappa binding. The results are consistent with the idea that the recognition sequence for RBP-Jkappa (GTGGGAA) overlaps that for NF-kappaB (GGGAATTCCC). This analysis, and the fact that slower migrating complexes that contain both NF-kappaB and RBP-Jkappa proteins were not observed (data not shown), also suggests that binding of either factor is exclusive.
###end p 34
###begin title 35
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 36 39 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
The CYP2B1/2 NF-kappaB element is a cis-acting repressor of transcription
###end title 35
###begin p 36
###xml 199 207 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 437 438 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 604 610 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 611 612 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 669 672 625 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1018 1019 966 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f2">2</xref>
###xml 1024 1025 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f4">4</xref>
To determine whether binding of RBP-Jkappa to the NF-kappaB 2B1/2 element is responsible for a functionally distinct effect on gene expression compared to the NF-kappaB Igkappa element, we performed in vitro transcription assays. Tandem NF-kappaB 2B1/2 or NF-kappaB Igkappa sites were cloned into pMLG4G, a template that drives expression of a G-free cassette under the control of the AdML core promoter (-49 to +10). As shown in Figure 6A, transcription from pMLG4G-2B1/2 (lane 2) was ~6-fold lower compared to the pMLG4G-Igkappa template (lane 1). This result suggests that the NF-kappaB site from the CYP2B1/2 gene, but not the NF-kappaB Igkappa site, is a negative cis-acting regulatory element. Addition of an NF-kappaB 2B1/2 oligonucleotide competitor had no effect on pMLG4G-Igkappa transcription (lane 3), but restored transcription of pMLG4G-2B1/2 to normal levels (lane 4). The selective reversal of pMLG4G-2B1/2 inhibition by this oligonucleotide and the protein-DNA interaction assays presented in Figures 2 and 4 suggest that RBP-Jkappa is responsible for repression.
###end p 36
###begin p 37
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 27 28 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 107 114 107 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 484 485 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 519 520 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 545 551 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 552 553 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 807 808 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 229 233 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
To confirm that the CYP2B1/2 element, but not the IgK element, would down-regulate a heterologous promoter in vivo (as predicted by the experiment in Fig. 6A), CYP2B1/2 and Igkappa NF-kappaB sites were positioned upstream of the SV40 promoter-luciferase reporter in the pGL3-Pro vector. The parental vector and each of the derived constructs were transfected into COS-7 cells with or without 3 microg of a pCMV-RBP expression vector that encoded a 68 kDa myc-tagged RBP protein (Fig. 6B, lane 2). The results in Figure 6C show that the pGL3-Pro-CYP2B1/2 promoter activity, as measured by luciferase activity, was repressed in the presence of pCMV-RBP. In contrast, the pGL3-Pro and pGL3-Pro-Igkappa constructs, which do not contain RBP recognition sequences, were unaffected. The right hand panel in Figure 6C shows that repression increased (17, 28 and 57%) with increasing amounts of co-transfected pCMV-RBP (1, 2 and 5 microg).
###end p 37
###begin title 38
Formation of NF-kappaB, RBP-Jkappa and other protein-DNA complexes does not differ in control and PB-treated extracts
###end title 38
###begin p 39
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 441 447 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 448 449 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 526 527 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f7">7</xref>
###xml 1081 1083 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c33">33</xref>
###xml 1084 1086 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c34">34</xref>
###xml 1098 1100 1078 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c35">35</xref>
###xml 1101 1103 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c36">36</xref>
###xml 272 276 <span type="species:ncbi:10116">rats</span>
###xml 674 677 <span type="species:ncbi:10116">rat</span>
A unique characteristic of the CYP2B1/2 promoters is their transcriptional up-regulation in response to PB treatment. For this reason we wanted to test whether NF-kappaB or RBP-Jkappa binding activities were altered in hepatic extracts prepared from saline- or PB-treated rats. To do so, we first normalized the amounts of each extract preparation on the basis of their ability to form complexes with oligonucleotide probes that spanned the CYP2B1/2 core promoter (-45 to -13) or with an AdML TATA element, as shown in Figure 7 (lanes 1-4). We then tested a panel of synthetic oligonucleotides that contained binding sites for several transcription factors present in adult rat liver. Extracts prepared from control (C) and induced (I) animals 20 h post-treatment showed ~2-fold or less change in the binding of RBP-Jkappa (lanes 7 and 8), NF-kappaB (lanes 5-8), AP-1 (lanes 9 and 10), Sp1 (lanes 11 and 12) or C/EBP (lanes 13 and 14). Each of the shifted complexes observed in this assay was competed specifically (data not shown). It has been suggested elsewhere that NF-kappaB (33,34) and AP-1 (35,36) activities increase in hepatic nuclear extracts following PB treatment. Although the basis for these differences is not known, we conclude here that RBP-Jkappa is a constituitive negative factor.
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin p 41
###xml 75 81 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 82 83 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 267 269 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c32">32</xref>
###xml 475 477 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c37">37</xref>
###xml 478 480 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c38">38</xref>
###xml 505 507 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c39">39</xref>
###xml 625 632 585 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 735 736 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f1">1</xref>
###xml 831 837 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP450</italic>
###xml 1058 1060 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c40">40</xref>
###xml 1166 1168 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c17">17</xref>
###xml 1199 1204 1135 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 71 74 <span type="species:ncbi:10116">rat</span>
###xml 619 624 <span type="species:ncbi:10090">mouse</span>
In this study we have identified an atypical NF-kappaB site within the rat CYP2B1/2 MaLR element that is recognized by the inducible NF-kappaB and constituitive RBP-Jkappa/CBF1 transcription factors. Assuming a concensus RBP-Jkappa recognition sequence of G/ATGGGAA (32), the occurrence of dual NF-kappaB/RBP-Jkappa elements is predicted to occur at ~12.5% of NF-kappaB sites that contain the GGGAA NF-kappaB half site. This element, together with similar sites in the IL-6 (37,38) and NF-kappaB-2 genes (39), defines a functionally distinct subclass of NF-kappaB recognition sequences. Interestingly, the PB-inducible mouse CYP2b10 gene also contains a putative RBP-Jkappa element that occurs in the context of a NF-kappaB site (Fig. 1B). However, a search for NF-kappaB and RBP-Jkappa sites in the promoter regions of additional CYP450 genes did not reveal other examples of sites that overlap. It is interesting to note that another class of atypical NF-kappaB sites are G-C rich and are proposed to be the site of an interplay between NF-kappaB and Sp1 (40). The data also make the important point that a widely distributed family of repetitive elements, MaLRs (17), can contain sites that bind trans-acting transcriptional regulatory factors.
###end p 41
###begin p 42
###xml 120 122 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c18">18</xref>
###xml 391 396 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BamHI</italic>
###xml 446 448 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c41">41</xref>
###xml 449 451 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c47">47</xref>
###xml 495 505 483 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 533 555 517 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Suppressor of Hairless</italic>
###xml 596 601 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch</italic>
###xml 643 645 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c48">48</xref>
###xml 745 747 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c49">49</xref>
###xml 851 853 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c50">50</xref>
###xml 868 870 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c37">37</xref>
###xml 871 873 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c38">38</xref>
###xml 892 894 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c39">39</xref>
###xml 1103 1105 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c51">51</xref>
###xml 1284 1286 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c52">52</xref>
###xml 1426 1428 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c53">53</xref>
###xml 1429 1431 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c54">54</xref>
###xml 290 308 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 495 505 <span type="species:ncbi:7227">Drosophila</span>
###xml 856 861 <span type="species:ncbi:9606">human</span>
RBP-Jkappa was originally isolated based on its recognition of an immunoglobulin kappa gene recombination signal probe (18) and functions either as a cofactor-dependent positive regulator or, in the absence of additional proteins, as a negative regulator. For instance, RBP-Jkappa recruits Epstein-Barr virus nuclear antigen-2 (EBNA-2) protein to sites in the viral latent membrane protein, BamHI C, terminal protein and cellular CD23 promoters (41-47), where it up-regulates transcription. The Drosophila counterpart of RBP-Jkappa, Suppressor of Hairless, mediates transcriptional activation by Notch through a similar mechanism (reviewed in 48) and both EBNA-2 and mammalian Notch1 interact directly with RBP-Jkappa to activate transcription (49). By itself, however, RBP-Jkappa is able to repress gene expression. For instance, the adenovirus pIX (50), human IL-6 (37,38) and NF-kappaB-2 (39) promoters are repressed by RBP-Jkappa. Moreover, Gal4-RBP-Jkappa fusion proteins inhibit transcription from a herpes simplex virus thymidine kinase core promoter construct that contains upstream Gal4 sites (51). The mechanism of repression by RBP repression at sites near the TATA element may involve interference with the function of the general transcription factor TFIIA bound to TBP (52). RBP-Jkappa is also associated with a histone deacetylase that could negatively modulate transcription factor accessibility to chromatin (53,54).
###end p 42
###begin p 43
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c2">2</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c5">5</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c3">3</xref>
###xml 455 462 455 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c10">10</xref>
###xml 589 595 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 596 597 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 623 630 615 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 760 766 748 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 767 768 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 952 953 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f3">3</xref>
###xml 998 999 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f3">3</xref>
###xml 1107 1113 1087 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1114 1115 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1201 1209 1181 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1237 1238 1217 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 1379 1387 1359 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1449 1451 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c50">50</xref>
###xml 1465 1471 1441 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1472 1473 1448 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1521 1528 1493 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1688 1689 1652 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f6">6</xref>
###xml 1811 1818 1767 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1874 1876 1830 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c37">37</xref>
###xml 449 454 <span type="species:ncbi:10090">mouse</span>
###xml 585 588 <span type="species:ncbi:10116">rat</span>
###xml 617 622 <span type="species:ncbi:10090">mouse</span>
###xml 1551 1555 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Induction of the CYP2B1/2 genes by chemical inducers involves a positively acting PBRE that binds a transcriptional activator(s) responsive to PB (reviewed in 2-5). The function of such factors may be to overcome, or derepress, the effects of negatively acting sequences that appear to maintain these genes in a relatively inactive state (reviewed in 3). Repression is strikingly illustrated by the ability of sequences between -971 and -775 of the mouse CYP2b10 promoter to reduce the activity of a heterologous thymidine kinase promoter (10). As the NF-kappaB/RBP-Jkappa site in the rat CYP2B1/2 (-888 to -882) and mouse CYP2b10 (-894 to -888) promoters is within this negative regulatory region, our studies suggest a role for RBP-Jkappa in down-regulating CYP2B1/2 gene expression. This idea is supported by several observations. First, RBP-Jkappa is an abundant factor whose levels, as shown in this report, are not affected by PB treatment (Fig. 3). Moreover, subcellular fractionation (Fig. 3) and immunolocalization experiments (data not shown) show that RBP-Jkappa is a nuclear factor. Second, the CYP2B1/2 site represses transcription from the heterologous AdML core promoter in a cell-free in vitro transcription system (Fig. 6). The degree of repression observed (~6-fold) is comparable to that observed with the adenovirus pIX promoter and a partially reconstituted in vitro transcription system to which purified RBP-Jkappa was added (50). Third, the CYP2B1/2 NF-kappaB element also represses transcription in vivo from the heterologous SV40 promoter in COS-7 cells, an effect not seen with a similar NF-kappaB site from the IgK enhancer that does not bind RBP-Jkappa (Fig. 6). Similarly, a related NF-kappaB/RBP-Jkappa element from the IL-6 gene interleukin response element repressed expression in vivo when positioned ~1.2 kb away from the initiation site (37). Of course, it is possible that additional transcriptional regulatory proteins that bind the MaLR may also help to down-regulate CYP2B1/2 gene expression.
###end p 43
###begin p 44
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 239 245 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 246 247 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 577 583 553 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 584 585 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 742 744 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c37">37</xref>
###xml 937 939 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c37">37</xref>
###xml 940 942 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd338c39">39</xref>
###xml 960 961 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd338f3">3</xref>
###xml 1000 1001 948 949 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1386 1392 1326 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1393 1394 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
Several additional questions arise from our findings. For instance, are the CYP2B1/2 promoters activated by interactions between the mammalian Notch transcriptional activator or EBNA-2 proteins and promoter-bound RBP-Jkappa? Also, are the CYP2B1/2 or other genes that contain dual NF-kappaB/RBP-Jkappa elements controlled by an interplay of the cognate binding factors, or does competition from RBP-Jkappa help mainly to re-establish repressed transcription levels more rapidly on dual NF-kappaB/RBP-Jkappa sites? While the current study is limited to a demonstration that the CYP2B1/2 element is a negative regulatory element, in the case of the IL-6 gene RBP-Jkappa is able to diminish the NF-kappaB-mediated response to TNFalpha and IL-1 (37). Displacement of RBP-Jkappa by NF-kappaB would be facilitated by an increase in nuclear NF-kappaB concentrations following induction and by the higher affinity of NF-kappaB-DNA interactions (37,39). Indeed, Figure 3 also shows that the intensity of the C1 complex and the upper NF-kappaB complexes in nuclear extracts is ~11:1 in the absence of dissociating reagents (e.g. lane 1), but is nearly 1:1 following activation (lane 5). If these results reflect the abundance of NF-kappaB binding activities in the nucleus following the response to physiological inducers, they suggest the potential for an interplay between these factors on the CYP2B1/2 NF-kappaB site. However, future work will be required to investigate these issues in more detail.
###end p 44
###begin p 45
###xml 362 368 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 369 370 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
In conclusion, the results here show that RBP-Jkappa/CBF1 acts as a constituitively active nuclear repressor whose binding site can in some instances overlap sites for the NF-kappaB transcriptional activator. The activity of RBP-Jkappa/CBF1 at such elements may be to constituitively diminish transcription from nearby core promoters, for instance the uninduced CYP2B1/2 genes, or to modulate the effects of signaling pathways that activate NF-kappaB.
###end p 45
###begin title 46
Figures and Tables
###end title 46
###begin p 47
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 34 44 34 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP450 2B1</italic>
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B2</italic>
###xml 900 901 896 897 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 965 971 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 976 979 972 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B2</italic>
###xml 990 997 986 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 1017 1023 1013 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1028 1031 1024 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2B2</italic>
###xml 1237 1244 1225 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2b10</italic>
###xml 30 33 <span type="species:ncbi:10116">rat</span>
###xml 961 964 <span type="species:ncbi:10116">rat</span>
###xml 984 989 <span type="species:ncbi:10090">mouse</span>
###xml 1013 1016 <span type="species:ncbi:10116">rat</span>
###xml 1231 1236 <span type="species:ncbi:10090">mouse</span>
 (A) Schematic diagram of the rat CYP450 2B1 and 2B2 promoters. Core promoter binding factors, including TBP, C/EBP and Sp1, are indicated at the far right. CA refers to a repetitive CA sequence of five (2B1) or 19 (2B2) reiterations. The black arrow (-1242 to -739) pointing away from the core promoter indicates a solitary LTR from a family of mammalian apparant LTR retrotransposons (MaLR). The predicted boundaries between the U3, R and U5 regions of the LTR are shown in the expansion below, along with the position of putative NF-kappaB and polyadenylation (AATAAA) sites. GRE indicates the position of a glucocorticoid response element. The dark box centered around -2300 (PBRE) represents a distal enhancer that confers responsiveness to PB. Sequences further upstream consist of distinct regions of LINE-1 elements, as well as reiterated GA dinucleotide sequences. See text for references. (B) Comparison of selected sequences within the MaLR from the rat CYP2B1 and 2B2 and mouse CYP2b10 promoters. The rat CYP2B1 and 2B2 sequences are identical within the region shown and include a direct repeat (DR) of 12 nt. The putative NF-kappaB and RBP-Jkappa sites are shaded and indicated with arrows. The MaLR element from the mouse CYP2b10 promoter lacks the DR, but contains NF-kappaB and RBP-Jkappa sites.
###end p 47
###begin p 48
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 40 46 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 47 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 253 254 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 290 291 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 294 277 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 450 451 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 538 539 498 499 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 542 543 502 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1002 1003 942 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1005 1006 945 946 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1141 1142 1069 1070 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 36 39 <span type="species:ncbi:10116">rat</span>
###xml 93 96 <span type="species:ncbi:10116">rat</span>
 (A) The NF-kappaB element from the rat CYP2B1/2 MaLR LTR forms several shifted complexes in rat liver nuclear extracts. Band shift reactions contain probes for NF-kappaB Igkappa (lanes 1-3) or NF-kappaB 2B1/2 (lanes 4-6), as shown. One major complex (C1) and up to three minor complexes (C2-C4) were observed. Addition of unlabeled oligonucleotide competitors NF-kappaB Igkappa (lanes 2 and 5) and NF-kappaB 2B1/2 (lanes 3 and 6) indicate that the C1 complex is competed by the NF-kappaB 2B1/2 site, but not the NF-kappaB Igkappa site. (B) C1 complex formation is specific for the NF-kappaB 2B1/2 element. Reactions were performed using the NF-kappaB 2B1/2 probe as described in (A). Oligonucleotide competitors include none (lane 1), 2B1/2 core -43 to -13 (lane 2), NF-kappaB 2B1/2 (lane 3), NF-kappaB Igkappa (lane 4), 2B1/2 DR (lane 5), C/EBP (lane 6), AP-1 (lane 7), Sp1 (lane 8), AdML TATA (lane 9), AP-1-like site A (lane 10), AP-1-like site B (lane 11) and an AP-1 mutant (lane 12). The upper C2-C4 complexes are competed by both the NF-kappaB 2B1/2 and NF-kappaB Igkappa oligonucleotides (lanes 3 and 4), while competition for the C1 complex is seen only with NF-kappaB 2B1/2 (lane 3).
###end p 48
###begin p 49
###xml 366 367 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 125 128 <span type="species:ncbi:10116">rat</span>
 Localization and inducibility of protein-DNA complexes formed with the NF-kappaB 2B1/2 element. Extracts were prepared from rat liver nuclei (lanes 1-7) and cytoplasm (lanes 8-14) and tested for complex formation using the NF-kappaB 2B1/2 element as probe. Inducibility of complex formation was tested by the addition of DOC, formamide or NP-40, as indicated. The C1 complex (lanes 1-7) was restricted to nuclear extracts and was unaffected by treatment with dissociating reagents.
###end p 49
###begin p 50
 Supershift assays using antibodies against NF-kappaB subunits p50, p52 and p65 and against RBP-Jkappa. Band shift reactions contain HeLa cell nuclear extract (N.E., lanes 1-10) and a kinase-labeled NF-kappaB 2B1/2 probe. Reactions were carried out in the absence (lanes 1-5) or presence (lanes 6-14) of DOC and NP-40. Lanes 11-14 contain antibody alone. The results indicate that Ab-p50 (lanes 2 and 7) and Ab-p65 (lanes 3 and 8) supershift the upper complex, while Ab-RBP-Jkappa (lanes 5 and 10) supershifts the lower complex. The positions of RBP-Jkappa, NF-kappaB and supershifted complexes are indicated to the left.
###end p 50
###begin p 51
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 25 26 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 436 437 412 413 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
 (A) Sequences of CYP2B1/2 NF-kappaB mutant oligonucleotides. Sequences (top strand) of NF-kappaB 2B1/2 (oligo 1) and NF-kappaB Igkappa (oligo 2) oligonucleotides, and various point substitutions (oligos 3-12) are aligned. The relative ability of these oligos to compete for NF-kappaB and RBP-Jkappa binding activity is indicated to the right (100%, +++++; 80-100%, ++++; 60-80%, +++; 40-60%, ++; 20-40%, +; <20%, -/+; no binding, -). (B) Competition for NF-kappaB and RBP-Jkappa complex formation using mutant oligonucleotides. Oligonucleotides 1-12 were used as competitors in band shift reactions containing HeLa cell nuclear extracts and a labeled NF-kappaB 2B1/2 probe (lanes 1-12). Lane C shows a control experiment performed in the absence of competitor.
###end p 51
###begin p 52
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 36 42 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 43 44 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 118 126 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 182 190 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 365 373 345 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 570 571 546 547 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 779 780 739 740 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 884 890 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 891 892 847 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1084 1091 1024 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1122 1128 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1129 1130 1069 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1156 1162 1092 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1163 1164 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1228 1234 1164 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 1235 1236 1171 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 842 846 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
 (A) The NF-kappaB element from the CYP2B1/2 promoter represses transcription from the adenovirus major late promoter in vitro. Adenovirus major late (AdML) promoter-G-free cassette in vitro transcription templates containing two NF-kappaB Igkappa (pMLG4G-Igkappa) (lanes 1 and 3) or NF-kappaB 2B1/2 (pMLG4G-2B1/2) (lanes 2 and 4) sites were tested for activity in in vitro transcription experiments using HeLa cell nuclear extracts. Reactions were performed in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of the NF-kappaB 2B1/2 oligonucleotide competitor. (B) A myc-tagged RBP-Jkappa construct (pCMV-RBP-Jkappa) overexpresses RBP-Jkappa in COS-7 cells. RBP-Jkappa protein (68 kDa) was detected in extracts prepared 48 h post-transfection using anti-myc antibodies. (C) Overexpressed RBP-Jkappa protein reduces expression from an SV40 promoter construct that contains the CYP2B1/2 NF-kappaB site. The left panel shows that a control vector (pGL3-Pro) and an IgK NF-kappaB site vector (pGL3-Pro-Igkappa) are not affected by co-transfection and overexpression of RBP-Jkappa in vivo, whereas a construct with the CYP2B1/2 NF-kappaB site (pGL3-Pro-CYP2B1/2) is reduced. The right panel shows that repression of pGL3-Pro-CYP2B1/2 is dependent on the amount of co-transfected pCMV-RBP-Jkappa.
###end p 52
###begin p 53
###xml 199 205 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2B1</italic>
###xml 206 207 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 95 98 <span type="species:ncbi:10116">rat</span>
 Formation of NF-kappaB, RBP-Jkappa and several other protein-DNA complexes does not differ in rat hepatic extracts prepared from control (C) or PB-induced animals (I). Oligonucleotides spanning the CYP2B1/2 core (-45 to -13) (lanes 1 and 2) and the AdML TATA element (lanes 3 and 4) were used to normalize activity of control (C) and PB-induced (I) extracts with respect to TATA element binding activities. Oligos tested include NF-kappaB Igkappa (lanes 5 and 6), NF-kappaB 2B1/2 (lanes 7 and 8), AP-1 (lanes 9 and 10), Sp1 (lanes 11 and 12) and C/EBP (lanes 13 and 14).
###end p 53
###begin title 54
ACKNOWLEDGEMENTS
###end title 54
###begin p 55
We thank Dr Jing Hong Mu and Ashok Upadhyaya for reading the manuscript. We acknowledge the generous gift of anti-RBP-Jkappa K0043 monoclonal antibody and RBP-2 cDNA from Dr Tasuku Honjo. Veterinary assistance was provided by Dr Tony Myers. This work was supported by the Welch Foundation.
###end p 55
###begin title 56
REFERENCES
###end title 56

